Jing Lu

Jing Lu

Auto-generated profile, based on publicly available information

Jing Lu

Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
YLYining Lan
Yining Lan
JLJing Lu
Jing Lu
SZShaohan Zhang
Shaohan Zhang
CJChunxiao Jie
Chunxiao Jie
CCChunyong Chen
Chunyong Chen
DCDaobin Cheng
Daobin Cheng
Background: Disturbed flow generates oscillatory shear stress (OSS), which in turn leads to endothelial inflammation and atherosclerosis. Piezo1, a biomechanical force sensor, plays a crucial role in the cardiovascular system. However, the specific role of Piezo1 in atherosclerosis remains to be fully elucidated. Methods and Results: We detected the expression of Piezo1 in atherosclerotic mice and endothelial cells from regions with disturbed blood flow. The pharmacological inhibitor Piezo1 inhibitor (GsMTx4) was used to evaluate the impact of Piezo1 on plaque progression and endothelial inflammation. We examined Piezo1's direct response to OSS in vitro and its effects on endothelial inflammation. Furthermore, mechanistic studies were conducted to explore the potential molecular cascade through which Piezo1 mediates endothelial inflammation in response to OSS. Our findings revealed the upregulation of Piezo1 in apoE−/− (apolipoprotein E) atherosclerotic mice, which is associated with disturbed flow. Treatment with GsMTx4 not only delayed plaque progression but also mitigated endothelial inflammation in both chronic and disturbed flow‐induced atherosclerosis. Piezo1 was shown to facilitate calcium ions (Ca 2 + ) influx in response to OSS, thereby activating endothelial inflammation. This inflammatory response was attenuated in the absence of Piezo1. Additionally, we identified that under OSS, Piezo1 activates the Ca 2 + /CaM/CaMKII (calmodulin/calmodulin‐dependent protein kinases Ⅱ) pathways, which subsequently stimulate downstream kinases FAK (focal adhesion kinase) and Src. This leads to the activation of the OSS‐sensitive YAP (yes‐associated protein), ultimately triggering endothelial inflammation. Conclusions: Our study highlights the key role of Piezo1 in atherosclerotic endothelial inflammation, proposing the Piezo1–Ca 2+ /CaM/CaMKII‐FAK/Src‐YAP axis as a previously unknown endothelial mechanotransduction pathway. Piezo1 is expected to become a potential therapeutic target for atherosclerosis and cardiovascular diseases.

22 December 2025 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
JLJing Lu
Jing Lu
ZQZuoyu Qin
Zuoyu Qin
YLYining Lan
Yining Lan
JZJianlin Zhang
Jianlin Zhang
ZYZhilin Yu
Zhilin Yu
YTYanyan Tang
Yanyan Tang
Antithrombin (AT) deficiency, often caused by mutations in the SERPINC1 gene, is a well-established risk factor for venous thromboembolism (VTE), which can

29 December 2025 in World Neurosurgery
Verified
Journal Article
Open access
XCXiuen Chen
Xiuen Chen
TZTing Zhou
Ting Zhou
CXChao Xiao
Chao Xiao
YLYining Lan
Yining Lan
DCDandan Chen
Dandan Chen
CQChao Qin
Chao Qin
The clinical efficacy of endovascular recanalization in patients with non-acute intracranial arterial occlusion (NAICAO) remains controversial. We conducted a systematic search in 3 databases (PubMed, EMBASE, and Web of science core) for endovascular recanalization for the treatment of NAICAO series cases according to PRISMA guidelines. Twenty-three articles with 1571 patients were included, with 1529 undergoing endovascular recanalization and 42 receiving conservative drug therapy alone. The overall success rate of endovascular recanalization was 87% (95% CI: 0.84-0.91, I2 = 78%); the rate of periprocedural complications was 13% (95% CI: 0.10-0.15, I2 = 48%); the periprocedural mortality rate was 0% (95% CI: 0.00-0.01, I2 = 0%); and imaging follow-up in patients with successful recanalization showed that overall restenosis and reocclusion rate were 15% (95% CI: 0.13-0.18, I2 = 17%); long-term follow-up stroke recurrence and mortality in the successful recanalization group was 7% (95% CI: 0.04-0.09, I2 = 67%); and in long-term follow-up stroke recurrence and mortality were significantly lower in the successful recanalization group than in the failure to recanalize group (odds ratio [OR]: 0.15, 95% CI: 0.06-0.37, I2 = 45%, P < 0.01). In a subgroup analysis of technical success, the success rate of anterior circulation did not differ from that of posterior circulation (OR:1.45,95% CI: 0.95-2.20, I2 = 0%, P = 0.08); similarly, there was no difference in the rate of perioperative complications between anterior and posterior circulation (OR: 1.25,95% CI: 0.67-2.31, I2 = 0%, P = 0.48). In NAICAO, endovascular recanalization presents a good safety and efficacy. Endovascular recanalization could be another option for patients with NAICAO ineffective on medical treatment.